Chimp Adenovirus -based Ebola vaccine-Looks promising

A promising new study shows that a recombinant chimp adenovirus-3 vaccine vector carrying the surface glycoproteins of Zaire and Sudan strains of Ebola virus was safe and immunogenic in 20 volunteers. There were 11 women and 9 men in the study and the ages ranged from 25-50.

Results

1. What looked really promising was that in about 70-90% of the participants, the vaccine induced antibodies to  Zaire and Sudan glycoproteins.

2. Glycoprotein-specific memory CD4 and CD8 T cell responses were polyfunctional and the vaccine elicited high proportions of CD8 cells co-producing interferon-g and TNF.

3. Pre-existing antibodies against adenovirus-3 did not significantly correlated with the magnitude of vaccine-induced memory CD4 T cell response.

Remarks

* While the CD4 T cell shows no significant change in cytokine response with increased particle units, the polyfunctionality of CD8 T cells shows a significant change.

* The graphs representing "Total Cytokine Response shown as a percent of subset" could be shown on a different scale on the Y axis to bring up a few of the dots that seem to lie close to zero.

Comments

Post a Comment

Popular posts from this blog

Coronavirus and Vaccine Development

Coronavirus Vaccine Update: In addition to VBI Vaccines Inc. (Ottawa, Canada), the following firms are as of 27 March 2020 beginning Phase 1 testing Phase I vaccine candidates   Company:  Moderna Vaccine candidate:  mRNA-1273 Details:  Moderna is the Massachusetts-based biotech company behind mRNA-1273, a vaccine candidate developed using prior studies of related coronaviruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Study Design:  A Phase 1, open-label, dose-ranging clinical trial of 45 healthy participants between 18-55 years old Institution:   Kaiser Permanente Washington Health Research Institute Status:  Recruiting completed 19 March 2020 ClinicalTrials.gov Identifier:   NCT04283461 Funding:  NIAID   Company:  CanSino Biologics Vaccine candidate:  Ad5-nCoV Details:  China’s CanSino Biologics has developed a recombinant novel coronavirus vaccine that incorporates...
Read more

Francoise-Barre-Sinoussi: a legend

Image
http://mosaicscience.com/story/francoise-barre-sinoussi An interesting article that is full of life, yet poignant, considering the lives lost to the disease and the impact of a discovery on the strained relationships between scientists. A terrific article describing the life and work of Francoise Barre-Sinoussi, the co-discoverer of the HIV virus.
Read more

Absurd claims by the Nation of Islam regarding Ebola?

A recent article found on finalcall.com is making the rounds on social media.  In a nutshell, the Minister of the Nation of Islam claims that the western world conducted a massive clinical trial of an Ebola vaccine just before the latest  outbreak in West Africa that killed several thousands. Again conspiracy theorists are out to make Ebola as a man-made disaster that is killing Africans. There are some true facts in the story, particularly those about ZMapp being made available to a select few and not available to a large number of patients, especially poor Africans! It would have created quite an outrage if the ZMapp antibody was administered to poor Africans and many died!! The fact that it was tried on some Americans point to the fact that ZMapp did not want to be named and shamed as a company that uses poor Africans as guinea pigs. It is pathetic that scientific facts are not debated intelligently before publication in obscure publications that promote conspiracy theor...
Read more